search
Back to results

Efficacy of Steroid Versus Steroid Plus Cyclophosphamide for Severe Henoch-Schoenlein Purpura

Primary Purpose

Henoch-Schoenlein Purpura

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Cyclophosphamide
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Henoch-Schoenlein Purpura focused on measuring Vasculitis, Cyclophosphamide, Renal failure

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients with Henoch-Schoenlein purpura Patient's age > 18 years Exclusion criteria: Patient presenting a purpura RHEUMATOID the diagnosis of which is confirmed by the histology presenting at least a visceral infringement(achievement) making consider the affection as engraves(burns) of 18 or more years old Patient Patient capable of understanding(including) the advantages and the risks of the try Patient having given his assent lit in writing

Sites / Locations

  • Hôpital LARIBOISIERE

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

1

Arm Description

Cyclophosphamide

Outcomes

Primary Outcome Measures

Birmingham Vasculitis Activity Score (BVAS)
Birmingham Vasculitis Activity Score (BVAS)

Secondary Outcome Measures

Chronic lesions (Vasculitis Damage Index)
Chronic lesions (Vasculitis Damage Index)
Renal function at 12 months
Renal function at 12 months
Kidney survival at 12 months
Kidney survival at 12 months
Patient survival at 12 months
Patient survival at 12 months
Blood pressure
Blood pressure
Infections
Infections
Adverse events related to steroid or cyclophosphamide
Adverse events related to steroid or cyclophosphamide

Full Information

First Posted
September 13, 2005
Last Updated
May 3, 2011
Sponsor
Assistance Publique - Hôpitaux de Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT00190229
Brief Title
Efficacy of Steroid Versus Steroid Plus Cyclophosphamide for Severe Henoch-Schoenlein Purpura
Official Title
CESAR (Randomized Therapeutic Study of Steroid vs. Steroid Plus Cyclosphosphamide for Severe Viscera Henoch-Schoenlein Purpura)
Study Type
Interventional

2. Study Status

Record Verification Date
March 2007
Overall Recruitment Status
Completed
Study Start Date
September 2002 (undefined)
Primary Completion Date
January 2008 (Actual)
Study Completion Date
January 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Assistance Publique - Hôpitaux de Paris

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Henoch-Schonlein purpura is a leucocytoclastic systemic vasculitis involving small vessels with the deposition of immune complexes containing IgA. It is characterized by the association of skin, joint and gastrointestinal manifestations. Even though the evolution is usually simple, some patients, especially adults, may have severe visceral involvement including heart, lung, brain and renal disease. The best treatment is currently unknown. This study will test the safety and efficacy of steroids associated or not with cyclosphosphamide to treat the acute lesions and to prevent the development of chronic lesions.
Detailed Description
The protocol test the role of 2 modalities of treatment (steroid vs. steroid and cyclophosphamide) for severe systemic form of Henoch-Schonlein purpura. The severe forms include extracapillary glomerulonephritis, myocarditis, pneumonitis, occult involvement, severe gastro-intestinal bleeding. No other randomized trial has been performed in adult patient for this indication.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Henoch-Schoenlein Purpura
Keywords
Vasculitis, Cyclophosphamide, Renal failure

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Cyclophosphamide
Intervention Type
Drug
Intervention Name(s)
Cyclophosphamide
Intervention Description
Cyclophosphamide
Primary Outcome Measure Information:
Title
Birmingham Vasculitis Activity Score (BVAS)
Description
Birmingham Vasculitis Activity Score (BVAS)
Time Frame
during de study
Secondary Outcome Measure Information:
Title
Chronic lesions (Vasculitis Damage Index)
Description
Chronic lesions (Vasculitis Damage Index)
Time Frame
during the study
Title
Renal function at 12 months
Description
Renal function at 12 months
Time Frame
during the study
Title
Kidney survival at 12 months
Description
Kidney survival at 12 months
Time Frame
during the study
Title
Patient survival at 12 months
Description
Patient survival at 12 months
Time Frame
during the study
Title
Blood pressure
Description
Blood pressure
Time Frame
during th study
Title
Infections
Description
Infections
Time Frame
during the study
Title
Adverse events related to steroid or cyclophosphamide
Description
Adverse events related to steroid or cyclophosphamide
Time Frame
during the study

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with Henoch-Schoenlein purpura Patient's age > 18 years Exclusion criteria: Patient presenting a purpura RHEUMATOID the diagnosis of which is confirmed by the histology presenting at least a visceral infringement(achievement) making consider the affection as engraves(burns) of 18 or more years old Patient Patient capable of understanding(including) the advantages and the risks of the try Patient having given his assent lit in writing
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eric THERVET, MD
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hôpital LARIBOISIERE
City
Paris
ZIP/Postal Code
75015
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
11961015
Citation
Pillebout E, Thervet E, Hill G, Alberti C, Vanhille P, Nochy D. Henoch-Schonlein Purpura in adults: outcome and prognostic factors. J Am Soc Nephrol. 2002 May;13(5):1271-8. doi: 10.1097/01.asn.0000013883.99976.22.
Results Reference
result
PubMed Identifier
20505654
Citation
Pillebout E, Alberti C, Guillevin L, Ouslimani A, Thervet E; CESAR study group. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schonlein Purpura. Kidney Int. 2010 Sep;78(5):495-502. doi: 10.1038/ki.2010.150. Epub 2010 May 26.
Results Reference
derived

Learn more about this trial

Efficacy of Steroid Versus Steroid Plus Cyclophosphamide for Severe Henoch-Schoenlein Purpura

We'll reach out to this number within 24 hrs